Related Experiment Video
Updated: Jul 31, 2025
10:32
Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
18.5K
A new era for schizophrenia drug development - Lessons for the future.
Kiri T Granger1, Michael Sand2, Sheryl Caswell3
1Monument Therapeutics, Macclesfield, UK; School of Psychology, University of Nottingham, Nottingham, UK.
Drug Discovery Today
|May 4, 2023
Summary
A new schizophrenia treatment, Karuna Therapeutics
Area of Science:
- Psychiatry and neuroscience research.
- Pharmacological treatments for mental health disorders.
- Clinical trial methodologies in drug development.
Background:
- Current schizophrenia treatments primarily target dopamine, often causing significant side effects impacting patient quality of life.
- Developing novel, effective treatments for schizophrenia has faced numerous challenges and failures.
- There is a critical need for new therapeutic options with improved side effect profiles.
Purpose of the Study:
- To evaluate the efficacy and safety of a novel, primarily non-dopamine-based treatment for schizophrenia.
- To assess the potential of Karuna Therapeutics' investigational drug as a new treatment option.
- To explore advancements in schizophrenia drug development methodology.
Main Methods:
- Phase III clinical trial evaluating Karuna Therapeutics' investigational drug.
- Focus on a treatment mechanism distinct from traditional dopamine antagonism.
- Assessment of efficacy in managing psychotic symptoms and safety/tolerability profile.
Main Results:
- Karuna Therapeutics reported positive results from its Phase III study.
- The investigational treatment shows potential for reduced or differentiated side effects compared to existing therapies.
- The study suggests a viable new therapeutic avenue for schizophrenia.
Conclusions:
- The success of Karuna Therapeutics' Phase III study marks a significant advancement in schizophrenia treatment.
- This non-dopamine-based approach offers a promising new option for patients, potentially improving quality of life.
- The study's outcomes highlight crucial lessons learned in schizophrenia drug development methodology.
Related Concept Videos
01:28Drug Therapy
76
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
76
01:26Psychosis: Goals of Pharmacotherapy
173
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
173
01:28Psychosis and Antipsychotic Drugs: Overview
365
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
365
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
785
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
785
01:26Drug Administration and Therapy Phases: Overview
589
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
589
01:29Psychological and Sociocultural Causes of Schizophrenia
150
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
150